The Neuren (ASX:NEU) share price is falling today despite positive news

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is climbing higher today. This comes after the company announced that it received Orphan designation for its second lead drug candidate, NNZ-2591.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price has changed direction today despite positive news on its drug trials

In early morning trade, the biopharma company's shares were up 2.7% to $1.50. But the Neuren share price has since sunk 3.75% to $1.41 at the time of writing. The All Ordinaries Index (ASX: XAO) is also down today, currently 0.45% lower at 6992 points.

good news and bad for asx shares represented by same man pictured happy and then sad

Image source: Getty Images

A quick take on Neuren

Based in Victoria, Australia, Neuren develops therapies for an array of neurodevelopmental and neurodegenerative disorders. The company currently has 2 key drug products in the pipeline, NNZ-2566 and NNZ-2591. The first of which is aimed at treating Rett syndrome and Fragile X syndrome. Both are currently in phase 3 and phase 2 trials, respectively.

The second drug in development, NNZ-2591, is advancing to provide remedy for Phelan-McDermid, Angelman and Pitt Hopkins syndromes. Neuren is conducting phase 1 trials with plans to commence phase 2 sometime this year.

What did Neuren announce?

Neuren has been granted received three Orphan designations for its second lead drug candidate, NNZ-2591. This treats Phelan-McDermid, Angelman and Pitt Hopkins syndromes. 

The favourable decision from the European Commission was based on the recommendations of the European Medicines Agency (EMA).

Orphan designation relates to a company receiving bonus benefits from achieving incentivised targets. This includes free protocol assistance, fee reductions, and 10 years of market exclusivity within the European Union. The period can be extended with a further 2 years if the company is approved for paediatric use.

That means that no other similar product can be granted a marketing authorisation approval from the EMA or EU countries.

About the Neuren share price

The Neuren share price has fallen more than 45% in the past 12 months.

The company's shares hit a multi-year high of $3.04 in February before COVID-19 sent shockwaves throughout the world. The result left the Neuren share price plummeting to a 52-week low of 96.5 cents.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ASX Share Market News

A woman's hand draws a stylised 'Top Ten' on a projected surface.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a rather unhappy hump day for the markets.

Read more »

Time to sell written on a clock.
Broker Notes

Sell alert! Why this expert is calling time on Xero and Northern Star shares

A leading expert forecasts ongoing headwinds for Xero and Northern Star shares. But why?

Read more »

Five young people sit in a row having fun and interacting with their mobile phones.
ASX Share Market News

Why Evolution Mining, Whitehaven and Santos shares are creating a buzz on Wednesday

Whitehaven, Evolution Mining and Santos shares are turning heads today. But why?

Read more »

A business person directs a pointed finger upwards on a rising arrow on a bar graph.
Broker Notes

Up 118%! Are PLS shares now a buy, hold or sell?

A leading expert provides his outlook for PLS' surging shares.

Read more »

Happy investor on tablet with finance graphs rising in overlay.
Broker Notes

Buy, hold, sell: ANZ Bank, Iress, and JB Hi-Fi shares

Here's what Morgans thinks of these shares following recent updates.

Read more »

Man looking at digital holograms of graphs, charts, and data.
ASX Share Market News

Could the AI boom just be getting started for NextDC shares?

AI is fuelling a data centre expansion, putting this ASX tech firmly in the spotlight.

Read more »

A man casually dressed looks to the side in a pensive, thoughtful manner with one hand under his chin, and holding a mobile phone in his other hand.
Broker Notes

Is the CSL share price in the buy zone after the biotech giant's results?

Is the biotech giant a buy following its results release?

Read more »

ASX 200 bank share trading depicted by red buy and sell dice tumbling across a sheet of data in colourful graphics
Broker Notes

With $30 billion in FY26 income, should I buy CBA shares today?

A leading analyst digs into the outlook for CBA’s slipping shares.

Read more »